Abstract
Objective
Ureteral stent replacement is a routine treatment for hydronephrosis in patients with
cervical cancer. We developed an improved ureteral stent-change operation for hydronephrosis
in cervical cancer patients and compared its outcomes with traditional stent change
procedures.
Study design
Clinical data of hydronephrosis in cervical cancer patients who were admitted to our
hospital from August 2014 to October 2019 were analyzed. We retrospectively reviewed
131 cervical cancer patients, out of which 43 cases included patients in the improved
operation group, whereas 88 patients with hydronephrosis followed the traditional
ureteral stent-change operation for ureteral obstruction. The outcomes of the two
procedures were compared using the propensity score matching method.
Results
As opposed to the traditional ureteral stent change strategy, the patients in the
improved group required shorter operation time (p=0.001) and higher success rate (p=
0.004). The FIGO stage (p=0.046), the level of ureteral obstruction (p=0.027), radiotherapy
history (p=0.01), stent replacement times (≤2times or>2times) (p=0.001), and serum
creatinine level (≤200μmol/L or>200μmol/L) (p<0.001) were significantly different
between the two groups before propensity score matching. Propensity score matching
analysis was used to eliminate the clinical differences of 43 patients in the traditional
group; however, the span of visual hematuria during the surgical complications was
not included (p=0.026) in the results.
Conclusion
An improved ureteral stent change operation is an advanced treatment option for cervical
cancer patients suffering from hydronephrosis. In contrast to traditional ureteral
stent change techniques, our developed strategy lowers complications such as visual
hematuria but improves the success.
Abbreviations:
HPV (Human Papilloma Virus), BMI (Body Mass Index), CT (Computed Tomography), MRI (magnetic resonance imaging), FIGO (Federation International Gynecology and Obstetrics), KUB X-ray (Kidney-Ureter-Bladder X-ray), IBM Corp (International Business Machines Corporation)Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Obstetrics and Gynecology and Reproductive BiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer.Hum Vaccin Immunother. 2016; 12: 1332-1342https://doi.org/10.1080/21645515.2015.1108500
- Hydronephrosis in patients with cervical cancer: an assessment of morbidity and survival.Support Care Cancer. 2015; 23: 1303-1309https://doi.org/10.1007/s00520-014-2482-y
- Effect of hydronephrosis on survival in advanced stage cervical cancer.Asian Pac J Cancer Prev. 2015; 16: 4219-4222https://doi.org/10.7314/apjcp.2015.16.10.4219
- Hydronephrosis as a prognostic indicator of survival in advanced cervix cancer.Int J Gynecol Cancer. 2011; 21: 1091-1096https://doi.org/10.1097/IGC.0b013e31821cabc8
- Stents for malignant ureteral obstruction.Asian J Urol. 2016; 3: 142-149https://doi.org/10.1016/j.ajur.2016.04.002
- Survival outcomes of patients with cervical cancer and accompanying hydronephrosis: A systematic review of the literature.Oncol Rev. 2019; 13: 387https://doi.org/10.4081/oncol.2019.387
- Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study.Gynecol Oncol. 2010; 117: 270-275https://doi.org/10.1016/j.ygyno.2010.01.045
- Outcomes of indwelling metallic stents for malignant extrinsic ureteral obstruction.Int J Urol. 2018; 25: 258-262https://doi.org/10.1111/iju.13500
- Metallic ureteral stents in malignant ureteral obstruction: clinical factors predicting stent failure.J Endourol. 2014; 28: 729-734https://doi.org/10.1089/end.2013.0792
Wong LM, Cleeve LK, Milner AD, Pitman AG. Malignant ureteral obstruction: outcomes after intervention. Have things changed? J Urol. 2007;178(1):178-183; discussion 183. 10.1016/j.juro.2007.03.026
- Ureteral stent placement and percutaneous nephrostomy in the management of hydronephrosis secondary to cervical cancer.Eur J Obstet Gynecol Reprod Biol. 2019; 241: 99-103https://doi.org/10.1016/j.ejogrb.2019.08.020
- Current outcome of patients with ureteral stents for the management of malignant ureteral obstruction.J Urol. 2011; 185: 556-561https://doi.org/10.1016/j.juro.2010.09.102
- Use of percutaneous nephrostomy and ureteral stenting in management of ureteral obstruction.World J Nephrol. 2016; 5: 172-181https://doi.org/10.5527/wjn.v5.i2.172
- The use of internal stents in chronic ureteral obstruction.J Urol. 2015; 193: 1092-1100https://doi.org/10.1016/j.juro.2014.10.123
- Ureteral stents for malignant extrinsic ureteral obstruction: outcomes and factors predicting stent failure.Int J Clin Oncol. 2019; 24: 306-312https://doi.org/10.1007/s10147-018-1348-6
- Serum creatinine predicts success in retrograde ureteral stent placement in patients with pelvic malignancies.Urology. 2008; 72: 370-373https://doi.org/10.1016/j.urology.2007.12.068
- Predicting factors for stent failure-free survival in patients with a malignant ureteral obstruction managed with ureteral stents.Korean J Urol. 2013; 54: 316-321https://doi.org/10.4111/kju.2013.54.5.316
- Outcomes of Ureteral Stent Placement for Hydronephrosis in Patients with Gynecological Malignancies.Curr Urol. 2017; 10: 126-131https://doi.org/10.1159/000447165
- Outcomes of stent-change therapy for bilateral malignancy-related ureteral obstruction.Int Urol Nephrol. 2015; 47: 19-24https://doi.org/10.1007/s11255-014-0858-z
- Nonoperative urinary diversion for malignant ureteral obstruction.Cancer. 1987; 60: 1353-1357https://doi.org/10.1002/1097-0142(19870915)60:6<1353::aid-cncr2820600632>3.0.co;2-5
- Would the indwelling internal ureteral stent influence renal function despite relief of benign ureteral obstruction?.J Endourol. 2014; 28: 243-247https://doi.org/10.1089/end.2013.0521
- Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy?.Gynecol Oncol Rep. 2019; 28: 136-140https://doi.org/10.1016/j.gore.2019.04.007
Article info
Publication history
Accepted:
January 22,
2023
Received in revised form:
December 12,
2022
Received:
June 2,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Elsevier B.V. All rights reserved.
